Full text is available at the source.
Abstract
Nicotinamide mononucleotide (NMN) may improve metabolic dysfunction caused by high glucose/high fat conditions in diabetic cardiomyopathy.
- High glucose/high fat conditions are associated with metabolic dysfunction in diabetic cardiomyopathy.
- NMN is investigated for its potential role in this metabolic dysfunction.
- The mechanism may involve stabilization of CPT1A, a protein important for fatty acid metabolism, through SIRT1.
- Findings suggest that NMN could help in managing metabolic issues related to diabetic cardiomyopathy.
Simplified